Design and Rationale of TRITON-PN, a Phase Three Study to Evaluate the Efficacy of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Onpattro (patisiran) - Alnylam, Sanofi

nucresiran (ALN-TTRsc04) - Alnylam

Amvuttra (vutrisiran) - Alnylam

https://www.aan.com/msa/Public/Events/AbstractDetails/64136

Laura Piera Obici1; Karla Cárdenas-Soto2; Marcia Waddington-Cruz3; Violaine Plante-Bordeneuve4; Ines Losada5; Thomas Brannagan6; Julian Gillmore7; John Berk8; JuanJuan Li9; K. H. Vincent Lau9; Alejandra Gonzalez-Duarte10

Mar 6, 2026